

Bioresonance therapy in the treatment of reactive arthritis

K.G. Khachumova

(homeopathic center Vitality, Moscow, Russia)

Reactive arthritis (ReA) account for 10% of patients in rheumatological hospitals [7], and urogenic arthritis accounts for 50–75% of all ReA. This is due to the prevalence of sexually transmitted diseases and the increased level of laboratory diagnostics of urogenic infections, which makes it possible to establish the correct diagnosis.

The term "reactive arthritis" is used to denote aseptic inflammation in the joints, which has developed in close connection with any infection. In this case, the pathogen and its antigens cannot be detected in the joint cavity [1]. The most significant etiological factor in the development of urogenic arthritis is currently recognized as chlamydia (*Chlamidia trachomatis*). Another pathogen is mycoplasma. Mycoplasma and chlamydiae are obligate parasites and can reproduce only intracellularly and cannot be detected by conventional culture methods. Chlamydia is determined by direct immunofluorescence, enzyme immunoassay, PCR reaction.

Chlamydia infection in healthy men and women is 5-10%, in patients with urinary tract disease, this infection is detected in 20-60% of cases. Ureaplasma infection is isolated in 30-50% of patients with urogenic arthritis [5].

In the pathogenesis of arthritis associated with infection, there are 2 phases: infectious (early) and immunopathological (late). In the late phase of the disease, microbial antigens are rarely detected.

According to a number of authors [4, 7, 8, 10, 11, 12], chlamydia affects the cells of the articular cartilage. Chlamydial persistence maintains the inflammatory process and makes standard anti-inflammatory therapy for arthritis ineffective.

In connection with the above data, new approaches to the treatment of ReA based on bioresonance therapy (BRT) are highly relevant.

Over the past 2 years, 34 patients with reactive arthritis have been treated in the hospital. Chlamydia was diagnosed in 24, arthritis was associated with intestinal infection in 3, yersinia and ureaplasma infection were detected in 7 patients. All patients had inflammatory changes in more than 3 joints. In 84% of cases there was synovitis, in 70% - fever, in 7% - conjunctivitis. All patients were treated in a hospital with the inclusion of antibacterial therapy, anti-inflammatory, in severe cases - hormonal therapy, basic therapy. After 3 weeks of treatment, the patients had hyperthermia in 9% of cases, joint pain - 45%, synovitis - 12%, limitation of mobility of more than 3 joints - 26%. After discharge from the hospital, the patients continued to be followed up for 6 months and were divided into 2 groups: those who continued taking the drugs prescribed in the hospital and the 2nd group, who received BRT,

Table 1

Dynamics of the studied parameters against the background of the therapy

Study timing	1 month		3 months		6 months	
Study groups	1 gr.	2 gr.	1 gr.	2 gr.	1 gr.	2 gr.
Pain in more than three joints	36%	eighteen%	thirty%	-	15%	-
Synovitis	eleven%	ten%	6%	-	3%	-
Limited joint mobility	19%		17%		nine%	
ESR more than 20 mm / h	40%	37%	28%	19%	23%	eleven%

According to the study, it was found that the use of BRT allows to achieve a clinical effect at an earlier date. The absence of a protracted and chronic course of the disease in the study group of patients and side effects of drugs, allergies during treatment proves the advantage of this therapy in patients with reactive arthritis.

Discussion

Reactive arthritis, according to the literature, has recently been prone to subacute (3-6

months) and a protracted course in 2/3 of patients [9], there is also a primary chronic or recurrent course. Often, after a year of the course of reactive arthritis during treatment with basic drugs and the continued activity of the process, the diagnosis is revised towards ankylosing spondylitis, and the patient receives a disability group within the first 3-5 years. With timely initiation of treatment with the use of bioresonance therapy ReA in all cases, we had a positive clinical effect. When diagnosing by the ART method, all patients were tested for chlamydia, ureaplasma, yersinia in combination with Cocksackie, Epstein-Barr viruses, cytomegalovirus, streptococci and staphylococci, which was confirmed by laboratory in 50% of cases. A more severe course was observed with mixed infection.

The positive results of treatment are due to the draining function of BRT, an increase in cellular immunity, and the normalization of metabolic processes, which is confirmed by the following clinical examples.

Clinical example 1

Patient K., 19 years old, was admitted with complaints of temperature up to 38.3 °, pain in the joints of the hands, feet, knees, synovitis of the right knee joint, left ankle. I fell ill after 2 weeks in the field of abdominal surgery, when after a rise in temperature, antibacterial therapy with amoxicillin was carried out. A week later, the temperature rises again to 38 °. A study was carried out for intestinal infections, ultrasound of the abdominal cavity, X-ray of the lungs, blood culture for sterility, ECHO KG, study of the joint fluid, immunoglobulins for the viral and bacterial group of infections. A low titer of Ig G for ureaplasma was determined, and the patient was transferred to the rheumatology department.

Two courses of therapy with cephalosporins, ciprolet in a therapeutic dose were carried out, but no clinical effect was obtained. A study was carried out for ACCP, HLA B27, LE cells, X-ray of the pelvic bones, knee, hands and feet, diagnosed with reactive arthritis. Sulfasalazine therapy was started according to the scheme, prednisolone 10 mg. After discharge from the hospital, the patient's synovitis recurred twice a month, despite the ongoing therapy and intra-articular injections on an outpatient basis.

When diagnosed by the ART method, chlamydial, ureaplasma infection, yersineosis, adenovirus infection, streptococcus and staphylococcus were revealed. The therapy was carried out with sorbents, enzymes, BRT according to the method of Hovsepyan, preparations of the company "SANUM". After 2 weeks, synovitis was not detected, the temperature returned to normal, a runny nose began, which lasted 3 weeks, after which the pain in the joints decreased significantly, the patient went to school. After 2 months, hormonal and basic therapy were canceled, the patient's condition improved, pain in the joints did not bother, movement was in full, laboratory parameters were normalized, sacroiliitis was not determined by X-ray. The therapy with nosodes continues.

Clinical example 2

Patient K., 54 years old, applied to the rheumatology department due to edema of the proximal phalanges of the hands, joint stiffness, complaints of morning stiffness in them. Joint pains bothered for 3 years, disappeared on their own or after anti-inflammatory ointments. History of type II diabetes mellitus, insulin-dependent; multinodular goiter, euthyroid state. Objectively: the patient has increased nutrition, the skin is clean, the peripheral lymph nodes are not enlarged. The wrist joint is thickened and painful, the proximal joint of the 2nd phalanx on the left. In the analyzes: ESR - 20 mm / h, leukocytes - 8.8×10^9 g / l, Hb - 125, e - 4.3×10^9 , ACCP, HLA B27 - negative, X-ray - osteoarthritis stage 2, osteoporosis. In the study for yersineosis - a low titer of Ig G. Diagnosed with deforming arthrosis, nodular form. Despite the ongoing therapy with vascular, anti-inflammatory drugs, the patient's joint pain persisted.

The study on ART revealed yersinia, helminthic invasion, strepto- and staphylococci, herpes virus types 1 and 2, BRT therapy was carried out according to the Hovsepyan method, enzymes, probiotics. Joint pains were completely stopped after the first procedure, however, skin rashes appeared that lasted 2 months. Currently, the skin has cleared, joint pains do not bother.

Thus, BRT is the most effective and gentle method of treating protracted and chronic forms of reactive arthritis in both urogenital and intestinal infections.

Literature

1. Asner T.V., Goryaev Yu.A., Makarenko S.P. Clinical variants of the chronic course urogenic reactive arthritis // Abstracts. reports of the 2nd All-Russian Congress of Rheumatologists.- Tula, 1997. - pp.10-11.
 2. Glazyrina G.A., Rusanova N.N., Lysenko O.V. Criteria for differential diagnosis of the disease Reiter and juvenile rheumatoid arthritis in children // Tez. reports of the 2nd All-Russian Congress of Rheumatologists. - Tula, 1997. - pp. 34-35.
 3. Nasonova V.A., Sigidin Ya.A. Pathogenetic therapy of rheumatic diseases. - M.: Medicine, 1985. -- 288 p.
 4. Panasyuk et al. On the pathogenetic aspects of urogenic arthritis associated with chlamydia: the ability of a microorganism to multiply in the cells of the articular cartilage // Therapist. archive. - 1998. - No. 5. - P.45-48.
 5. Skripkin Yu.K. et al. The problem of diagnosis and treatment of urogenital chlamydia in Russia // Antibiotics and chemotherapy. - 1996. - v. 41, No. 2. - P.5-8.
 6. Tvorogova T.M., Korovina N.A., Gavryushova L.P. Reactive arthritis in children // Russian medical journal. - 2006. - No. 5. - pp. 381-384.
 7. Ter-Vartanyan S.Kh., Kovchanich T.A., Solntseva T.M. Evaluation of the clinical efficacy of the drug Nimesulide-Darnitsa and Gel Remisar in the treatment of patients with reactive arthritis // Ukrainian rheumatological journal. - 2002. - No. 2. - P.262-264.
 8. Shubin S.V. Arthritis associated with urogenital infection // New medical journal. - 1996. - No. 1-2. - P.20-23.
 9. Eshbaev I.U., Soliev T.S. The role of urogenital infections in the development of reactive arthritis // Abstracts. reports of the 2nd All-Russian Congress of Rheumatologists. - Tula, 1997. -- S.202.
 10. Andersen B. et.al. // Fam. Pract. - 1998, Jun. 15 (3): 223-8.
 11. Bas S., Vicher TL // Br. J. Rheumatol. - 1998, 37 (10): 1054-9.
 12. Beutler AM, Schumacher HR // Br. J. Clin. Pract.-1997 Apr.-May 51 (3): 169-72.
-

Khachumova, K.G. Bioresonance therapy in the treatment of reactive arthritis / K.G. Khachumova // XXII International Conference "Theoretical and Clinical Aspects of the Application of Bioresonance and Multiresonance Therapy". - M.: IMEDIS, 2016. -- S.149-153.

[To favorites](#)